Call: 860-258-3470

Clinical Research


Starling is pleased to now offer our patients access to select clinical trials that have the power to transform the lives of patients around the world. Benefits to patients who participate include:

We currently are accepting patients for two clinical trials and will be adding more trials over time. Based on specific criteria, your Starling provider will determine if you are a candidate for a trial. A member of our research team will then reach out to you to discuss what you could expect if you chose to participate.

Study 1: Stand tall with SHIELD: a blood test to improve lung cancer screening

Cancer screening is an effective way to detect cancer early when it can most easily be treated. Unfortunately, many people today are not being screened in line with recommendations.

Guardant Health is addressing this shortcoming by developing LUNAR-2, a blood test that seeks to increase screening rates and overcome the challenges of current methods, all from a simple blood draw.

To accomplish these objectives, Guardant Health is leveraging data from the tens of thousands of cancer patients it has already tested, as well as collaborating with multiple investigators at cancer centers around the world.

We at Guardant Health believe a simple blood test can improve lung cancer screening by overcoming barriers associated with current methods, such as low-dose CT scans, while still being effective and more accessible.

To be considered for the study, participants must meet the following criteria:

Talk to your doctor today for more information on the Guardant LUNAR-2 test and the SHIELD study.

 

Study 2: A blood test to screen for multiple types of cancers

This study involves the analysis of a blood sample to screen for the presence of colon, breast, or lung cancer. During an office visit, the provider identifies patients who meet the following:

The patient would then be asked to give a blood sample to check for certain screening markers. Patients who participate in the study will be compensated for their participation.

Learn About This Trial

Study 3: Clinical biospecimen study to support the advancement of medical diagnoses of renal disease

The purpose of this study is to provide blood samples to medical researchers who are searching for better methods for detecting and/or treating renal disease. In order to qualify, participants must:

Study 4: CASCADE-LUNG using DELFI: a blood test to improve lung cancer screening

The goal of this study is to make screening easier and more accessible so people can live longer, cancer-free lives.  This study will help determine the ability of a simple blood-based screening technology to detect lung cancer accurately and reliably. In order to qualify, participants must:

Interested?   Click Here to sign up or for information.

 


If you believe you are a candidate for a study, discuss with your Starling provider. Or, reach out to our Clinical Research Coordinator: Kristine Calabrese.

Kristine Calabrese
Clinical Research Coordinator
kcalabrese@starlingphysicians.com 
(860) 224-6266 x6616